Compare · BDX vs SILK
BDX vs SILK
Side-by-side comparison of Becton Dickinson and Company (BDX) and Silk Road Medical Inc. (SILK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and SILK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $41.33B, about 38.8x SILK ($1.07B).
- BDX has hit the wire 10 times in the past 4 weeks while SILK has been quiet.
- Both have 25 recent analyst ratings on file.
- Company
- Becton Dickinson and Company
- Silk Road Medical Inc.
- Price
- $150.14-0.71%
- $27.50+0.02%
- Market cap
- $41.33B
- $1.07B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- News (4w)
- 10
- 0
- Recent ratings
- 25
- 25
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Silk Road Medical Inc.
Silk Road Medical, Inc. operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization. Its products includes ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices. The company was incorporated in 2007 and is headquartered in Sunnyvale, California.
Latest BDX
- Chairman, CEO and President Polen Thomas E Jr exercised 20,209 shares at a strike of $126.16, returned $2,549,587 worth of shares to the company (17,445 units at $146.15) and sold $404,511 worth of shares (2,764 units at $146.35) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 110,163 units (SEC Form 4)
- EVP and President, BDI Menziuso Peter was granted 14,258 shares (SEC Form 4)
- New insider Menziuso Peter claimed no ownership of stock in the company (SEC Form 3)
- Becton Dickinson and Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- EVP, Chief Revenue Officer Feld Michael sold $11,051 worth of shares (75 units at $147.35) as part of a pre-agreed trading plan, decreasing direct ownership by 0.35% to 21,084 units (SEC Form 4)
- SEC Form SD filed by Becton Dickinson and Company
- SEC Form CERT filed by Becton Dickinson and Company
- BD Delivers Kidney Stone Care for Urology Teams with the Elyra™ Thulium Fiber Laser System
- Becton Dickinson and Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Peter Menziuso Named EVP and President, BD Interventional
Latest SILK
- Boston Scientific Announces Results for Third Quarter 2024
- SEC Form 15-12G filed by Silk Road Medical Inc.
- SEC Form EFFECT filed by Silk Road Medical Inc.
- Amendment: SEC Form SC 13D/A filed by Silk Road Medical Inc.
- Director Zurbay Donald returned 12,610 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Weatherman Elizabeth H returned 155,004 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Lasersohn Jack W returned 16,735 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Chou Tony M. returned 85,251 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Carino Tanisha returned 11,396 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Ballinger Kevin J. returned 23,666 shares to the company, closing all direct ownership in the company (SEC Form 4)